Merck to lay off 200 as part of 5-year reorganisation plan

pharmafile | July 18, 2017 | News story | Manufacturing and Production Merck, biotech, drugs, healthcare, pharma, pharmaceutical 

German drug manufacturer Merck has announced its intention to streamline its manufacturing processes across Europe as part of a five-year reorganisation programme with a goal of accelerating its production response time to meet customer demand by optimising and centralising filling and distribution of its chemical products.

The reorganisation will affect sites across Germany, with facilities closing in Steinheim, Eppelheim, Hohenbrunn and Berlin and operations relocated, resulting in around 200 job losses until 2022. Merck will instead refocus these operations at Darmstadt and Schnelldorf in Germany, Molsheim in France, and Buchs in Switzerland, investing €90 million across the four sites.

“Centralising filling of small quantities and their distribution will continue to increase our speed and responsiveness to customer requests,” explained Udit Batra, CEO of Merck’s Life Science business. “This is something that the acquired Sigma-Aldrich excelled in and we see positive impacts of this effort already in North America.”

Advertisement

Merck acquired Sigma-Aldrich for $17 billion in 2014 – a move which appears have spurred the new direction for the company, with many anticipating layoffs following the merger.

A spokesperson for the company added: “Further development of these Centers of Excellence in key European locations intends to reduce complexity of the Life Science global supply chain, while increasing production capacity to secure future supply, speed to market and service levels to customers.”

Matt Fellows

Related Content

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly secures conditional MHRA approval for new blood cancer treatment

Crown Bioscience opens new US model development centre

Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …

The Gateway to Local Adoption Series

Latest content